The large majority of newly diagnosed BCs are early BC (eBC) and 15% to 20% of patients have tumours that exhibit overexpression of the Human Epidermal Growth Factor Receptor 2 (HER2) [2, 3]. Here, ERBB2 is linked to breast cancer.